JR
Insider
James Paul Rickey
Chief Financial OfficerJames Paul Rickey (Chief Financial Officer) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Braveheart Bio, Inc. (BRVE). Across 1 priced purchase filing, the average 21-session return was -10.0% from execution and -10.0% from disclosure (delay-adjusted; derived). The largest single filing was $500K of BRVE (27,777 sh × $18.00, as filed), executed Aug 7.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
-10.0%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
-10.0%
same 1 filings, from disclosure
Filings, ttm
1
1 buys · 0 sells
Median delay
0d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$500K
shares × price, as filed
Last traded
Aug 7
Filed Aug 7
Volume by month
Buys $500K
Sells $0
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
1 filing
Sector per market data · by filing · past 12 months
Most traded names
BRVERecent filings
BRVEPURCHASE
Braveheart Bio, Inc.
View filing →
$500K27,777 sh × $18.00
Exec Aug 7
Filed Aug 7 · 4:41 PM ET